The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy

OncoImmunology

Volumn 4, Issue 8, 2015, Pages

  Hirano, Kosuke ^a   Hosoi, Akihiro ^a,b   Matsushita, Hirokazu ^a   Iino, Tamaki ^a,b   Ueha, Satoshi ^c   Matsushima, Kouji ^c   Seto, Yasuyuki ^a   Kakimi, Kazuhiro ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b MEDINET Co Ltd   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

adoptive transfer; carboxy PTIO; CTL; myeloid derived suppressor cells (MDSCs); nitric oxide (NO)

Indexed keywords

GAMMA INTERFERON; NITRIC OXIDE; SCAVENGER; UNCLASSIFIED DRUG; [2(4(CARBOXYPHENYL) 4,4,5,5, TETRAMETHYLIMIDAZOLINE 1 OXYL 3 OXIDE];

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL FUNCTION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FLOW CYTOMETRY; IMMUNOFLUORESCENCE TEST; MALE; MELANOMA B16; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SUPPRESSOR CELL;

EID: 84940532097     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1019195     Document Type: Article

References (38)

1. D.Hanahan, A.Weinberg Robert. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
2. D.F.Quail, J.A.Joyce. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19:1423-37; PMID:24202395; http://dx.doi.org/10.1038/nm.3394
3. W.Zou. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; PMID:15776005; http://dx.doi.org/10.1038/nrc1586
4. I.Mellman, G.Coukos, G.Dranoff. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10673
5. D.Lindau, P.Gielen, M.Kroesen, P.Wesseling, G.J.Adema. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138:105-15; PMID:23216602; http://dx.doi.org/10.1111/imm.12036
6. S.Chen Daniel, I.Mellman. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
7. D.M.Pardoll. Immunology beats cancer: a blueprint for successful translation. Nat Immunol 2012; 13:1129-32; PMID:23160205; http://dx.doi.org/10.1038/ni.2392
8. D.S.Chen, B.A.Irving, F.S.Hodi. Molecular pathways: next-generation immunotherapy––inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18:6580-7; PMID:23087408; http://dx.doi.org/10.1158/1078-0432.CCR-12-1362
9. P.A.Ott, F.S.Hodi, C.Robert. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19:5300-9; PMID:24089443; http://dx.doi.org/10.1158/1078-0432.CCR-13-0143
10. N.P.Restifo, M.E.Dudley, S.A.Rosenberg. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
11. M.Kalos, H.June Carl. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39:49-60; PMID:23890063; http://dx.doi.org/10.1016/j.immuni.2013.07.002
12. C.June, S.A.Rosenberg, M.Sadelain, J.S.Weber. T-cell therapy at the threshold. Nat Biotech 2012; 30:611-4; PMID:22781680; http://dx.doi.org/10.1038/nbt.2305
13. A.Hosoi, H.Matsushita, K.Shimizu, S.-I.Fujii, S.Ueha, J.Abe, M.Kurachi, R.Maekawa, K.Matsushima, K.Kakimi. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Int J Cancer 2014; 134:1810-22; PMID:24150772; http://dx.doi.org/10.1002/ijc.28506
14. S.Noji, A.Hosoi, K.Takeda, H.Matsushita, Y.Morishita, Y.Seto, K.Kakimi. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy. J Immunother 2012; 35:460-72; PMID:22735804; http://dx.doi.org/10.1097/CJI.0b013e31826092db
15. A.Mazzoni, V.Bronte, A.Visintin, J.H.Spitzer, E.Apolloni, P.Serafini, P.Zanovello, D.M.Segal. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168:689-95; PMID:11777962; http://dx.doi.org/10.4049/jimmunol.168.2.689
16. S.Ostrand-Rosenberg, P.Sinha. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; PMID:19342621; http://dx.doi.org/10.4049/jimmunol.0802740
17. B.Almand, J.I.Clark, E.Nikitina, J.van Beynen, N.R.English, S.C.Knight, D.P.Carbone, D.I.Gabrilovich. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166:678-89; PMID:11123353; http://dx.doi.org/10.4049/jimmunol.166.1.678
18. C.M.Diaz-Montero, M.Salem, M.Nishimura, E.Garrett-Mayer, D.Cole, A.Montero. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/10.1007/s00262-008-0523-4
19. D.I.Gabrilovich, S.Ostrand-Rosenberg, V.Bronte. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
20. J.-I.Youn, S.Nagaraj, M.Collazo, D.I.Gabrilovich. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. JImmunol 2008; 181:5791-802; PMID:18832739; http://dx.doi.org/10.4049/jimmunol.181.8.5791
21. R.Wesolowsk, J.Markowitz, W.E.Carson. Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer. J Immunother Cancer 2013; 1:10; PMID:24829747; http://dx.doi.org/10.1186/2051-1426-1-10
22. K.A.Noonan, N.Ghosh, L.Rudraraju, M.Bui, I.Borrello. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol Res 2014; 2:725-31; PMID:24878583; http://dx.doi.org/10.1158/2326-6066.CIR-13-0213
23. D.T.Weed, J.L.Vella, I.M.Reis, A.C.De la Fuente, C.Gomez, Z.Sargi, R.Nazarian, J.Califano, I.Borrello, P.Serafini. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21:39-48; PMID:25320361; http://dx.doi.org/10.1158/1078-0432.CCR-14-1711
24. J.A.Califano, Z.Khan, K.A.Noonan, L.Rudraraju, Z.Zhang, H.Wang, S.Goodman, C.G.Gourin, P.K.Ha, C.Fakhry et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21:30-8; PMID:25564570; http://dx.doi.org/10.1158/1078-0432.CCR-14-1716
25. L.Gattinoni, D.J.PowellJr, S.A.Rosenberg, N.P.Restifo. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6:383-93; PMID:16622476; http://dx.doi.org/10.1038/nri1842
26. H.Matsushita, Y.Enomoto, H.Kume, T.Nakagawa, H.Fukuhara, M.Suzuki, T.Fujimura, Y.Homma, K.Kakimi. A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. J Immunother Cancer 2014; 2:30; PMID:25694811; http://dx.doi.org/10.1186/s40425-014-0030-4
27. C.Meyer, L.Cagnon, C.M.Costa-Nunes, P.Baumgaertner, N.Montandon, L.Leyvraz, O.Michielin, E.Romano, D.E.Speiser. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014; 63:247-57; PMID:24357148; http://dx.doi.org/10.1007/s00262-013-1508-5
28. Y.Pico de Coana, I.Poschke, G.Gentilcore, Y.Mao, M.Nystrom, J.Hansson, G.V.Masucci, R.Kiessling. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res 2013; 1:158-62; PMID:24777678; http://dx.doi.org/10.1158/2326-6066.CIR-13-0016
29. K.Movahedi, M.Guilliams, J.Van den Bossche, R.Van den Bergh, C.Gysemans, A.Beschin, P.De Baetselier, J.A.Van Ginderachter. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007-07-099226
30. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
31. L.Dolcetti, E.Peranzoni, S.Ugel, I.Marigo, A.Fernandez Gomez, C.Mesa, M.Geilich, G.Winkels, E.Traggiai, A.Casati et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010; 40:22-35; PMID:19941314; http://dx.doi.org/10.1002/eji.200939903
32. S.Kusmartsev, Y.Nefedova, D.Yoder, D.I.Gabrilovich. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172:989-99; PMID:14707072; http://dx.doi.org/10.4049/jimmunol.172.2.989
33. S.Nagaraj, K.Gupta, V.Pisarev, L.Kinarsky, S.Sherman, L.Kang, D.L.Herber, J.Schneck, D.I.Gabrilovich. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; PMID:17603493; http://dx.doi.org/10.1038/nm1609
34. T.Lu, R.Ramakrishnan, S.Altiok, J.I.Youn, P.Cheng, E.Celis, V.Pisarev, S.Sherman, M.B.Sporn, D.Gabrilovich. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011; 121:4015-29; PMID:21911941; http://dx.doi.org/10.1172/JCI45862
35. B.Molon, S.Ugel, F.Del Pozzo, C.Soldani, S.Zilio, D.Avella, A.De Palma, P.Mauri, A.Monegal, M.Rescigno et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208:1949-62; PMID:21930770; http://dx.doi.org/10.1084/jem.20101956
36. T.Akaike, M.Yoshida, Y.Miyamoto, K.Sato, M.Kohno, K.Sasamoto, K.Miyazaki, S.Ueda, H.Maeda. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry 1993; 32:827-32; PMID:8422387; http://dx.doi.org/10.1021/bi00054a013
37. H.Maeda, T.Akaike, M.Yoshida, M.Suga. Multiple functions of nitric oxide in pathophysiology and microbiology: analysis by a new nitric oxide scavenger. J Leukoc Biol 1994; 56:588-92; PMID:7964166
38. W.W.Overwijk, M.R.Theoret, S.E.Finkelstein, D.R.Surman, L.A.de Jong, F.A.Vyth-Dreese, T.A.Dellemijn, P.A.Antony, P.J.Spiess, D.C.Palmer et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198:569-80; PMID:12925674; http://dx.doi.org/10.1084/jem.20030590